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tissue engineering aims to rectify. In many early cases of OA, it has 
CFFOJEFOUJ¾FEUIBUUIFMPTTPGDBSUJMBHFUJTTVFJTUIFNBJOTZNQUPN
Since the initial stages of OA involve increased cell proliferation 
and synthesis of matrix proteins, proteinases and cytokines in the 
cartilage, laboratory investigations have focused on the chondrocyte 
as a target for therapeutic intervention. However, it is known that 
adult articular chondrocytes have limited capacity to regenerate the 
normal cartilage matrix and the damage is irreversible unless the 
destruction process is interrupted. However, OA is not appropriate 
for tissue engineering based on our knowledge of this joint disease. 
In order to answer the question whether OA is an appropriate clinical 
UBSHFU GPS DBSUJMBHF UJTTVF FOHJOFFSJOH XF NVTU ¾STU MPPL BU UIF
pathogenesis of OA. Many studies have shown that osteoarthritis 
affects not only the cartilage but both the subchondral bone and the 
TZOPWJBM¿VJE"TUVEZTIPXFE UIBUTVCDIPOESBMCPOF SFNPEFMJOH
plays an important role in the pathogenesis of OA, showing that it 
is not merely a cartilage disorder. ALN or other inhibitors of bone 
resorption could potentially be used as disease-modifying agents in 
the treatment of OA. By employing cartilage tissue engineering, the 
micro-environment in the synovial space remains largely unchanged 
BOEJUJTMJLFMZUIBUUIFJO¿BNNBUJPOBOEEFHSBEBUJPOPGUIFDBSUJMBHF
will persist despite attempts at tissue engineering. Hence, cartilage 
tissue engineering, which only addresses the issue of cartilage 
degeneration, seems to be unable to tackle the problems brought 
about by advanced stages of OA. Even in cases of early OA, research 
has shown in equine joints that distinct biochemical changes 
were detected in the cartilage, subchondral and trabecular bone, 
suggesting that OA is more than a simple case of cartilage defect 
brought about by degeneration. Next stage – Gene therapy? At later 
stages, cartilage tissue engineering with or without gene therapy 
XJUIBOBCPMJDGBDUPSTXJMMBMTPSFRVJSFUIFSBQZUPJOIJCJUJO¿BNNBUJPO
and block damage to newly repaired cartilage. Recent studies have 
proven that people may be genetically pre-disposed to OA, which 
points towards the presence of certain genes. Tissue engineering as a 
treatment for osteoarthritis is extremely challenging. Transplantation 
PGHFOFUJDBMMZNPEJ¾FEDFMMTJTBOJOUFSFTUJOHDPODFQUCBTFEPOUIF
production of therapeutic proteins directly at the target site. 
Conclusion Cell therapy will be a viable treatment option. However 
we will also need to employ scaffolds and growth factors to help 
solve the problems of both the bone and the cartilage prevalent in 
osteoarthritis. 
8.2
Will regenerated cartilage slow down the disease process in 
osteoarthritis?
A.P. Hollander8,B¾FOBI88ZMEF"#MPN6OJUFE,JOHEPN
The use of cells to repair articular cartilage is at an exciting stage 
of development as an approach to the treatment of joint disorders. 
Until now the application of autologous chondrocyte implantation 
(ACI) has been largely restricted to the repair of focal lesions and 
osteoarthritis (OA) has been considered as an exclusion criterion. 
However cartilage repair methods are generally becoming more 
sophisticated and the technology for growing mature cartilage using 
stem cells derived from older OA patients is now quite advanced. 
These advances in our technological capabilities have brought in to 
sharp focus the question of which OA patients if any we should treat 
using cartilage regeneration.
It is often argued that knee arthroplasty is such a successful 
operation that there is no need for a biological therapy. There is 
no doubt that those companies selling joint prostheses would 
encourage us to subscribe to this view. However there are three 
important reasons to challenge this dogma:
1. The subjective patient experience of a prosthesis may not 
match objective measurements of prosthesis survival or measures 
of improvement in range of motion and knee stability. In order to 
address this question we have recently undertaken a survey of 1725 
OA patients in the Bristol area 5-8 years after primary, unilateral hip 
or knee replacement surgery. The Oxford questionnaire was used 
to measure the patients’ experiences of pain and functional ability. 
In this way we have been able to show that patients who have 
VOEFSHPOFUPUBMLOFFSFQMBDFNFOUIBWFBTJHOJ¾DBOUMZXPSTF0YGPSE
score (more pain and less function) than those who have undergone 
UPUBMIJQSFQMBDFNFOU5IFTF¾OEJOHTBSFJOBDDPSEBODFXJUIPUIFS
studies of joint function after arthroplasty and raise concerns about 
UIFFG¾DBDZPGUPUBMLOFFSFQMBDFNFOUJOUIFUSFBUNFOUPG0"
2. Arthroplasty is now being used to treat much younger patients 
than was originally intended and this is likely to lead to a large 
increase in the numbers of patients requiring secondary and even 
tertiary implants following asceptic loosening. Delaying the time of 
UIF¾STUQSPTUIFTJTJNQMBOUBUJPOCZUIFVTFPGCJPMPHJDBMUIFSBQJFT
could play an important part in containing this problem.
3. There are growing concerns over the safety of implanting metal 
on metal prosthesis, particularly in younger patients, because of the 
generation of metallic wear debris that may directly induce genetic 
toxicity. Because the use of these implants in younger patients 
is a relatively recent phenomenon, we have not yet accumulated 
enough epidaemiological data to determine if arthroplasty is 
associated with increased carcinogenesis or with an increased 
incidence of congenital malformations where they have been 
implanted in women or men of child-bearing age. However it is clear 
that metal wear is capable of causing karyotpic changes that could 
theoretically lead to tumourogenesis or congenital defects.
Given these concerns, it makes sense to consider the possibility 
of using biological therapies that may be less invasive and more 
acceptable to younger OA patients. Until now exploration of this 
approach has been restricted to the realm of cartilage regeneration, 
with little regard for modifying the subchondral bone or the soft 
tissues of the joint. This focus on cartilage has been used as an 
argument against biological therapy. It is often suggested with 
HSFBU DPO¾EFODF UIBU SFQMBDJOH UIF DBSUJMBHFXJUIPVU UBDLMJOH UIF
underlying OA pathology is a waste of time. This may or may not 
be true. The assumption in this view of the world is that replacing 
DBSUJMBHFXPVMEIBWFOPJO¿VFODFPOUIFCJPMPHZPGUIFTVSSPVOEJOH
tissues. However it is equally possible that the very act of implanting 
new cartilage may lead to effective remodelling of other tissues and 
renewed joint stability. No doubt also there will be many patients 
who will require a combination of cartilage implantation and some 
other intervention (for example osteotomy to realign the joint and 
off-load the implant) in order to respond well to the newly engineered 
tissue. In an effort to begin to addres the question of whether or not 
implanted cartilage can survive and grow in an OA joint, we recently 
undertook a study of second look biopsies from patients treated 
with the Hyalograft C autologous chondrocyte therapy for focal knee 
DBSUJMBHFEFGFDUT8FJEFOUJ¾FEBTVCHSPVQPGUIFTFQBUJFOUTXIP
had X-ray evidence of pre-existing OA at the time of implantation. 
We therefore asked if the cartilage regenerated in these OA knees 
was of worse quality than that regenerated in the knees of patients 
with no evidence of OA at the time of implantation. Surprisingly 
we found that if anything the cartilage formed in the OA knees 
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was better than in those without pre-existing disease (Hollander et 
al). The implication is that the OA knee (at least in post-traumatic 
disease) is a good environment in which to implant a maturing 
tissue. At the very least these surprising data should remind us to 
keep an open mind as to the chances of successfully regenerating 
cartilage, even in patients with quite advanced disease.
In order to move to a point where we can maximise our chances 
of implanting mature cartilage engineered from chondrocytes or 
TUFNDFMMTXFOFFEUPIBWFTPNFDPO¾EFODFUIBUXFDBODSFBUFB
tissue that will have some mechanical stability and that will behave 
CJPMPHJDBMMZ JO B XBZ UIBU NBYJNJTFT UIF DIBODF UP JO¿VFODF UIF
disease process. In order to resurface large areas of denuded bone 
within an OA knee it will be necessary to create large sheets of 
cartilage and to ensure that it is as close to the articular cartilage 
QIFOPUZQF BT QPTTJCMF 'VSUIFSNPSF JU XJMM CF FTTFOUJBM UP ¾OE B
method of integrating this cartilage with surrounding natural tissues 
(cartilage and bone). We have made advances on both these fronts. 
Whilst some studies have suggested that OA bone marrow stem 
DFMMT BSF EF¾DJFOU JO UIFJS DIPOESPHFOJD DBQBDJUZ XF IBWF GPVOE
that in fact, given appropriate growth factor cues delivered at the 
right times, it is possible to engineer cartilage from these cells that 
is as good as anything that can be created using the best source 
of chondrocytes. Furthermore we can down-regulate the tendency 
of chondrocytes generated from stem cells to differentiate down 
the hypertrophic phenotype. With respect to integration, it seems 
probable that implantation of a mature cartilage will require co-
implantation of cells that can actively unite the implant and host 
tissues. We are attempting to achieve this using a “cell bandage” 
technology that could be used for a range of different tissues.
Commercial products are already available that are being implanted 
into large lesions without the use of integrating methodology. 
Hyalograft C (Fidia) and CaRes (Arthrokinetiks) could both potentially 
CF JNQMBOUFE JOUP MBSHF VODPO¾OFE MFTJPOT )PXFWFS UIFTF BSF
immature implants (mostly cells with very little extracellular matrix) 
and it is at present uncertain if they would provide mechanical 
stability early enough or quickly enough to stabilise the OA joint.
It is far too early to know if implantation of engineered cartilage, 
alone or in combination with other surgical interventions, can have 
B TJHOJ¾DBOU JNQBDU PO UIF QSPHSFTTJPO PG 0" *U JT DMFBS UIBU UIF
technology is fast approaching the point where such intervention 
is possible and that methods for implantation and integration will 
be available to us. Biological implants by their very nature are not 
passive and it is not unreasonable to pose the hypothesis that a 
living tissue implant will not just provide a mechanical replacement 
for lost cartilage but could also have a direct positive effect on the 
subchondral bone and surrounding tissues. Until this hypothesis 
has been tested in animal models and in patients we should keep an 
open mind about the place of tissue engineering and cell therapies 
in the treatment of OA.
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8.3
The clinician view 
M. Marcacci, E. Kon, B. Grigolo, M. Delcogliano, G. Filardo, M.P. 
Neri, Italy 
In recent years, several options have become available to treat 
cartilage lesions. Given the intrinsic limitations of these techniques, 
newer surgical approaches have been developed focused on 
obtaining a complete regeneration of the hyaline cartilage as well 
as a complete integration with the surrounding tissues, to restore 
the normal knee function and to provide durable outcomes. 
The cell-based approach, known as Autologous Chondrocyte 
*NQMBOUBUJPO	"$*
XBT¾STU JOUSPEVDFE JO4XFEFO JO5JTTVF
engineering strategy is based on the use of biodegradable polymers 
as temporary scaffolds for the in vitro growth of living cells and 
their subsequent transplantation into the defect site. Hyaluronic 
acid has proven to be an ideal molecule for tissue engineering 
strategies in cartilage repair, given its impressive multi-functional 
activity in cartilage homeostasis. Hyalograft® C Autograft (Fidia 
Advanced Biopolymers, Abano Terme, Italy) is a hyaluronan-based 
scaffold cultured with autologous chondrocytes. Three-dimensional 
nonwoven scaffolds based on HYAFF® 11 support the in vitro growth 
of highly viable chondrocytes and promote the expression of their 
original chondrogenic phenotype.2 Chondrocytes, previously 
expanded on plastic and seeded into the HYAFF® 11 scaffold produce 
a characteristic extracellular matrix rich in proteoglycans and 
express typical markers of hyaline cartilage, such as collagen II and 
aggrecan2,3 Some studies showed that differentiated phenotype 
of chondrocytes grown in monolayers in vitro can be restored 
CZ TFFEJOH UIF DFMMT JO B UISFFEJNFOTJPOBM DPO¾HVSBUJPO UIVT
BMMPXJOH UIF DFMMT UP SFFYQSFTT UIFJS TQFDJ¾D HFOFT TP JUXPVME
be possible to hypothesize a further use of this biomaterial in the 
treatment of early cartilage lesions also in OA patients. HYAFF® 11-
based tissue engineered cartilage implant showed good results in 
focal cartilage lesions,5,6,7,8 but it’s utilize in osteoarthritis was 
purely investigated. The cell-based therapies developed to date for 
cartilage are indicated only for acute cartilage defects; however, the 
more common diseases of articular cartilage, primarily osteoarthritis, 
usually result in more extensive damage, which is currently treated 
with total joint replacements. The possibility to treat early stage 
arthritic lesions with tissue engineered cartilage is very attractive. In 
this review, we will present our clinical experience with Hyalograft® C 
autologous chondrocyte implant on a three-dimensional Hyaluronan-
based matrix also in patients affected by osteoarthritis. 
Implant preparation and implantation The surgical technique for 
Hyalograft C autologous chondrocytes implant consists of two 
TUFQT5IF¾STUQSPDFEVSFDPOTJTUTPGBCJPQTZPGIFBMUIZDBSUJMBHF
for autologous chondrocyte cell culture. This is usually performed 
arthroscopically, when the chondral lesion has been observed, 
and the indication for ACI has been made. A 150–200 mg cartilage 
biopsy is taken from a nonweight bearing site of the articular surface 
(intercondylar notch) and sent to the processing center in a serum-
free nutritional medium. The following day the tissue is minced 
into smaller pieces and digested with 0.25% trypsin at 37_C for 
15 min and then with 300 U/ml collagenase type II (Worthington, 
Lakewood, NJ, USA) at 37 °C for 4 h in Ham’s F12. The digested 
material is centrifuged at 1,000 rpm for 10 min and the pellet is 
resuspended in Ham’s F12 containing 10% fetal calf serum (Sigma), 
1% penicillin–streptomycin, 1% L-glutamine, 1 ng/ml TGFb1, 1 
ng/ml insulin, 1 ng/ml EGF, and 10 ng/ml bFGF (all growth factors 
XFSFSFDPNCJOBOUBOEPGIVNBOTFRVFODF
$FMMTBSFBNQMJ¾FE JO
monolayer cultures up to three passages, then they were seeded 
onto Hyalograft C scaffolds (2x2 cm). 8x106 cells are resuspended in 
0.4 ml of medium (as above, but containing 50 mg/ml ascorbic acid), 
the cell suspension is pipetted onto the scaffold and the culture is 
kept at 37 °C, 5% CO2 overnight. The next day, additional medium 
is added to submerge the cell construct completely, whereas the 
medium is changed twice a week. Hyalograft C chondrocyte cultures 
are ready for shipment after 2 weeks in culture. The day of shipment 
the cell construct is washed exhaustively with PBS then sealed in a 
sterile plastic tray containing 4 ml of nutritional medium. The expiry 
time of the product once packaged is 72 h. The engineered graft was 
implanted at the lesion site by a mini-arthrotomy under regional or 
HFOFSBM BOFTUIFTJB JO B UPVSOJRVFUDPOUSPMMFE CMPPEMFTT ¾FME PS
when indicated, through arthroscopy using a customized instrument 
set.9 Before implantation, the articular cartilage lesion was debrided 
to have healthy cartilage surrounding the defect, taking care to 
minimize excessive bleeding at the site of implantation. Hyalograft®
$XBTDVUJGOFDFTTBSZUP¾UUIFEFGFDUBOEUIFOXBTTJNQMZQMBDFE
into the prepared lesion where in the majority of cases, it was stable 
XJUIPVU UIFOFFE GPS BOZ¾YBUJPONFUIPECFDBVTFPG UIF JOUSJOTJD
adhesive properties of the hyaluronan scaffold.10 Otherwise, in large 
